3.200USD+0.16%Mkt Cap: —P/E: —1d ago
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based …
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value240.03M $
Revenue (TTM)47.01M $
Gross Profit-37.95M $
Net Income (TTM)-73.95M $
Revenue/Share0.4640 USD
Last Price3.200 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees87
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS28106W1036
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-2.96
EV/Revenue5.11
P/S—
P/B4.11
EPS (TTM)-2.73
EPS (Forward)—
52W Range
2.81080% of range3.300
52W High3.300 USD
52W Low2.810 USD
Profitability
Gross Margin-80.75%
Oper. Margin-167.31%
EBITDA Margin-172.40%
Profit Margin-157.32%
ROE-118.82%
ROA-23.29%
Growth
Revenue Growth232.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-119.86M $
CapEx (TTM)—
FCF Margin-94.28%
FCF Yield—
Net Debt-196.13M $
Net Debt/EBITDA2.42
Balance Sheet
Debt/Equity14.73
Current Ratio3.19
Quick Ratio3.13
Book Value/Sh0.6860 USD
Cash/Share1.378 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.47.50M
Float115.50M
Insiders0.18%
Institutions79.20%
Technical
SMA 508.494 (-62.3%)
SMA 2008.688 (-63.2%)
Beta2.06
S&P 52W Chg20.80%
Avg Vol (30d)28.32K
Avg Vol (10d)4.68K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—